DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.

Combination therapy of DBPR807 with sorafenib or anti-PD-1 Ab has been shown to have better efficacy in HCC disease animal models implanted with HCA-1 or JHH-7 liver cancer cells than the single treatment of sorafenib or anti-PD-1 Ab. This novel combination protocol can simultaneously inhibit angiogenesis, enhance immune response and prevent cancer metastasis, leading to a new horizon of cancer treatment.

DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis and normalize tumor microenvironment as well as promote cytotoxic T-cell infiltration. Although DBPR807 treatment alone can prolong survival as effectively as sorafenib and anti-PD-1 Ab, however, its combination therapy with either of them can extend overall survival more significantly than monotherapy. As such, this newly developed combination therapy may confer HCC cancer patients with a new therapeutic strategy and may also have a great impact on other advanced cancers of high metastatic incidences.